Autopsy report · NCT01136746

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Low enrollment”

The sponsor’s own words in the registry.

Life of this trial

Registered 9 months before it started.
Ran for about 8 months before it stopped.
16 participants enrolled.
Results were posted on the registry 11 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Conditions: Hyperglycemia
Interventions: Human regular insulin; Insulin lispro; Insulin glargine
Participants: 16
Sites: 12
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.